ÂÜÀòÂÒÂ×

Marianne Uteng has held various positions in the biotechnology industry since 2020. In 2020, they were a Board Observer at Rappta Therapeutics. In 2021, they became a Board Observer at Amphista Therapeutics Limited, a Board Director at CatalYm GmbH, and a Principal at Novartis Venture Fund. In 2022, they became a Board Director at Epsilogen Ltd.

Marianne Uteng received their PhD in Cell Biology & Biophysics from the European Molecular Biology Laboratory (EMBL) between 2003 and 2008. Prior to that, they earned a Master's degree in Biochemistry from the University of Oslo (UiO) between 1997 and 2003.